Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Novacyt ( (FR:ALNOV) ) has provided an update.
Novacyt has reported its latest monthly activity under a liquidity agreement with Invest Securities, disclosing that between 1 and 31 March 2026 the broker bought 37,022 ordinary shares and sold 24,014 shares within a price range of €0.37 to €0.41. Following these transactions, the company holds 126,926 ordinary shares in treasury, which are non-voting and do not qualify for dividends.
The diagnostics group confirmed that its total number of ordinary shares stands at 72,588,088, establishing the basis for shareholders to calculate disclosure thresholds for changes in their holdings under French securities regulations. The update also reiterates that the liquidity agreement, first signed in 2016 and renewed with shareholder approval in 2025, is operated independently by Invest Securities to support trading liquidity in Novacyt’s shares, with any repurchased stock either cancelled or retained as treasury shares.
More about Novacyt
Novacyt is an international molecular diagnostics company focused on delivering genomic medicine through a broad portfolio of molecular assays, instrumentation and integrated workflows for human, animal and environmental health. Headquartered in Le Vésinet, France, with offices in the UK, Singapore, the US and Canada, it serves more than 65 countries and recently expanded its Asia-Pacific footprint via the acquisition of Southern Cross Diagnostics in Australia.
For a thorough assessment of ALNOV stock, go to TipRanks’ Stock Analysis page.